chr9-34648385-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000155.4(GALT):c.616C>T(p.Gln206*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,888 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000155.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- classic galactosemiaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Orphanet
 - galactosemiaInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen, Myriad Women’s Health
 
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  Cov.: 32 
GnomAD4 exome  AF:  6.84e-7  AC: 1AN: 1461888Hom.:  0  Cov.: 32 AF XY:  0.00000138  AC XY: 1AN XY: 727246 show subpopulations 
Age Distribution
GnomAD4 genome  Cov.: 32 
ClinVar
Submissions by phenotype
Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase    Pathogenic:3 
Variant summary: GALT c.616C>T (p.Gln206X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251484 control chromosomes (gnomAD). c.616C>T has been reported in the literature in individuals affected with Galactosemia, including one homozygote and one compound heterozygote with a second pathogenic allele (GALT c.584T>C [p.Leu195Pro] ClinVar:25222). These data indicate that the variant is associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One ClinVar submitter has assessed the variant since 2014: the variant was classified as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at